Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials

Oncbiomune to Advance Ovarian Cancer Vaccine into Clinical Trials
OncBioMune Pharmaceuticals is advancing its investigative ovarian cancer vaccine OvcaVax into human clinical trials to test its safety and efficacy in the adjuvant (after surgery) setting. OncBioMune announced it will meet in coming weeks to discuss trial protocol, location, and budget. OvcaVax works similarly to the company’s experimental vaccine ProscaVax, which targets the PSA protein in prostate

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *